A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Public ClinicalTrials.gov record NCT04538794. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.
Study identification
- NCT ID
- NCT04538794
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 24, 2020 (Actual)
- Primary completion
- Jan 17, 2023 (Actual)
- Completion
- Jan 17, 2023 (Actual)
- Last update posted
- Jul 19, 2023
2020 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Center of Alabama | Birmingham | Alabama | 35209 | — |
| Arizona Allergy & Immunology Research | Gilbert | Arizona | 85234 | — |
| Sarasota Clinical Research | Sarasota | Florida | 34239 | — |
| ForCare Clinical Research | Tampa | Florida | 33613 | — |
| Treasure Valley Medical Research | Boise | Idaho | 83706 | — |
| Midwest Allergy, Sinus and Asthma, SC | Normal | Illinois | 61761 | — |
| Dawes Fretzin Clinical Research | Indianapolis | Indiana | 46250 | — |
| Kanarek Allergy Asthma & Immunology | Overland Park | Kansas | 66211 | — |
| Bernstein Clinical Research Center, LLC | Cincinnati | Ohio | 45231 | — |
| Vital Prospects Clinical Research Institute, PC | Tulsa | Oklahoma | 74136-7028 | — |
| Asthma, Nasal Disease & Allergy Research Center of New England | East Providence | Rhode Island | 02914 | — |
| National Allergy and Asthma Research, LLC | North Charleston | South Carolina | 29420 | — |
| AARA Research | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04538794, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04538794 live on ClinicalTrials.gov.